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Aims Little evidence is available regarding restrictions from driving following implantable cardioverter deﬁbrillator (ICD)
implantation or following ﬁrst appropriate or inappropriate shock. The purpose of the current analysis was to
provide evidence for driving restrictions based on real-world incidences of shocks (appropriate and inappropriate).
Methods
and results
A total of 2786 primary and secondary prevention ICD patients were included. The occurrence of shocks was noted
during a median follow-up of 996 days (inter-quartile range, 428–1833 days). With the risk of harm (RH) formula,
using the incidence of sudden cardiac incapacitation, the annual RH to others posed by a driver with an ICD was
calculated. Based on Canadian data, the annual RH to others of 5 in 100 000 (0.005%) was used as a cut-off
value. In both primary and secondary prevention ICD patients with private driving habits, no restrictions to drive
directly following implantation, or an inappropriate shock are warranted. However, following an appropriate
shock, these patients are at an increased risk to cause harm to other road users and therefore should be restricted
to drive for a period of 2 and 4 months, respectively. In addition, all ICD patients with professional driving habits have
a substantial elevated risk to cause harm to other road users during the complete follow-up after both implantation
and shock and should therefore be restricted to drive permanently.
Conclusion The current analysis provides a clinically applicable tool for guideline committees to establish evidence-based driving
restrictions.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
It has been recognized that patients treated with an implantable
cardioverter deﬁbrillator (ICD) have an ongoing risk of sudden
incapacitation that might cause harm to others when driving a
car. Although numerous recommendations exist, thus far evidence
is scarce to justify them. As a result, a large variation exists
between different countries concerning the legislation of driving
restriction after both primary prevention and secondary preven-
tion ICD implantation.
1–3 Since driving restrictions are often
being perceived as difﬁcult for patients and their families, clear evi-
dence on the necessity of these restrictions is vital. Furthermore,
these restrictions should take into account the indication for
ICD implantation (primary or secondary prevention). In the end,
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doi:10.1093/eurheartj/ehr161however, it must be recognized that the goal of a zero per cent risk
is unobtainable and that society has to accept a certain level of risk
by allowing patients at risk to resume driving.
4–6
With the constant increase in ICD implants worldwide, clear
guidelines regarding driving restrictions in both primary and sec-
ondary ICD patients are warranted. In this analysis, we determined
the risk for ICD therapy following ICD implantation or following
previous device therapy (appropriate and inappropriate shock) in
relation with driving restriction for private and professional
drivers in a large number of primary and secondary ICD patients.
Methods
Patients
The study population consisted of patients from the south-western
part of the Netherlands (comprising 1 500 000 people) who received
an ICD for primary prevention or secondary prevention in the Leiden
University Medical Center, the Netherlands. Since 1996, all implant
procedures were registered in the departmental Cardiology Infor-
mation System (EPD-Vision
w, Leiden University Medical Center).
Characteristics at baseline, data of the implant procedure, and all
follow-up visits were recorded prospectively. The data collected for
the current registry ranged from January 1996 up to September 2009.
Eligibility for ICD implantation in this population was based on inter-
national guidelines for primary and secondary prevention. Due to evol-
ving guidelines, indications will have changed over time.
7,8
Device implantation and programming
All deﬁbrillator system implantations were performed transvenously,
without thoracotomy. Testing of sensing and pacing thresholds and
deﬁbrillation threshold testing was performed during the implant pro-
cedure. Implanted systems were manufactured by Biotronik (Berlin,
Germany), Boston Scientiﬁc [Natick, MA, USA, formerly CPI,
Guidant (St Paul, MN, USA)], Medtronic (Minneapolis, MN, USA),
and St Jude Medical/Ventritex (St Paul, MN, USA).
Deﬁbrillators were programmed as follows: a ventricular arrhythmia
monitor zone was programmed in all patients (150–188 b.p.m.). No
therapy was programmed in this zone until arrhythmias were detected
during follow-up. Ventricular arrhythmias faster than 188 b.p.m. were
initially attempted to be terminated with two bursts of antitachycardia
pacing (ATP) and, after continuation of the arrhythmia, device shocks
were the indicated therapy. Ventricular arrhythmias faster than
210 b.p.m. were directly attempted to be terminated by device
shocks. Furthermore, atrial arrhythmia detection was set to
.170 b.p.m. with supraventricular arrhythmia discriminators enabled.
Settings were adapted, only when clinically indicated (e.g. haemo-
dynamic well-tolerated ventricular tachycardia (VT) at high rate; VT
in the monitor zone).
According to Dutch legislation, updated in June 2004, private driving
was prohibited for the ﬁrst 2 months after implantation for both
primary prevention and secondary prevention ICD patients. Further-
more, private drivers are restricted from driving for a period of 2
months following an appropriate shock, and professional drivers are
permanently restricted from driving following ICD implantation.
9
Patient follow-up
Patient check-up was scheduled every 3–6 months, which included
device interrogation. In case of unplanned hospitalization or sympto-
matic episodes of arrhythmia, additional device interrogations were
performed. During device interrogation, episodes were assessed for
appropriate and inappropriate ICD therapy (ATP or shocks) and ver-
iﬁed by an electrophysiologist. Shocks were classiﬁed as appropriate
when they occurred in response to VT or ventricular ﬁbrillation
(VF) and as inappropriate when triggered by sinus tachycardia or
supraventricular tachycardia, T-wave oversensing, or electrode dys-
function. After delivery of an appropriate shock, efforts were made
by a trained electrophysiologist to reduce the recurrence rate of
arrhythmic events. When clinically indicated, ICD settings and/or
anti-arrhythmic medication were adjusted.
Since periodical follow-up was performed every 3–6 months,
patients without data for the most recent 6 months prior to the end
of the study were considered as lost to follow-up. However, these
patients were included in the analysis as far as data were acquired.
Endpoints
The ﬁrst shock (appropriate or inappropriate) was considered the
primary endpoint. For the second shock analysis, only those patients
who received a ﬁrst shock were considered at risk for a second
shock, and only subsequent shocks occurring .24 h after ﬁrst shock
were considered second shocks. Noteworthy, ATP therapy was
discarded from the analysis since the number of patients
experiencing syncope—and therefore incapacitation—during ATP
therapy is low.
10,11
Risk assessment
Currently, prospective controlled studies in which ICD patients have
been randomized to permit driving are not available. In 1992, a ‘risk
of harm’ formula was developed to quantify the level of risk to
drivers with ICDs by the Canadian Cardiovascular Society Consensus
Conference.
12,13 This formula, with the following equation: RH ¼
TD × V × SCI × Ac, calculates the yearly risk of harm (RH) to
other road users posed by a driver with heart disease and is directly
proportional to:
† proportion of time spent on driving or distance driven in a given
time period (TD),
† type of vehicle driven (V),
† yearly risk of sudden cardiac incapacitation (SCI),
† the probability that such an event will result in a fatal or injury
producing accident (Ac).
Based on the literature, it is known that on average a private driver
spends  4% (TD ¼ 0.04) and a professional driver spends  25%
(TD ¼ 0.25) of his time driving.
14,15 In addition, it was shown that
more injurious accidents were caused by heavy truck or passenger-
carrying vehicles when compared with private automobiles. In the
Ontario Road Safety Annual Report, truckers were involved in  2%
of all road accidents but in  7.2% of all lethal accidents. Based on
this data, V ¼ 1 for a professional driver and V ¼ 0.28 for a private
driver in the RH formula.
14,15 Furthermore, ,2% of reported incidents
of driver sudden death or loss of consciousness has resulted in injury
or death to other road users or bystanders (Ac ¼ 0.02).
16–18 In this
analysis, the yearly risk of SCI was based on the cumulative incidence
of ICD shocks (appropriate or inappropriate), which were calculated
for different follow-up periods as described previously. However,
the actual inﬂuence of an ICD shock on the capacity to drive is
unknown. According to the literature, 31% of the patients experience
syncope or near syncope during an appropriate shock.
19 Since this
proportion of patients receiving an appropriate shock will then be inca-
pacitated to drive, it was assumed that the SCI is equal to the cumu-
lative incidence of appropriate ICD shocks times 0.31. So far, no
reports exist that describe the proportion of patients experiencing
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causes of inappropriate shocks (atrial ﬁbrillation, sinus tachycardia,
T-wave oversensing, and lead failure), it is less likely that inappropriate
shocks coincide with more haemodynamic consequences than appro-
priate shocks do. With the assumption that 31% of the patients with
appropriate shocks experience syncope, it was supposed that at
most the same proportion of patients receiving an inappropriate
shock will experience syncope. Therefore, similar to appropriate
shocks, the SCI is equal to the cumulative incidence of inappropriate
ICD shocks times 0.31.
Considering the fact that driving restrictions for ICD patients are
implemented as a protection for both ICD patients, as well as other
road users, the RH formula is an easy tool to calculate the potential
harm brought to other road users on a yearly basis when ICD patients
are not restricted to drive.
Unfortunately, data regarding an acceptable level of risk for private
and professional drivers with an ICD in society are scarce. However, in
Canada an annual risk of death or injury to others of 5 in 100 000
(0.005%) appeared to be in general acceptable.
3 Therefore, this
generally accepted level of risk will be used as a cut-off value in the
current study.
Private and professional drivers
Criteria to distinguish a private driver from a professional driver were
deﬁned on the basis of the Canadian Cardiovascular Society Consen-
sus Conference.
12,13 According to these criteria, a private driver was
deﬁned as follows: (i) driving ,36 000 km per year; (ii) spending
,720 h per year driving; (iii) driving a vehicle weighting ,11 000 kg,
and (iv) does not earn a living by driving. Any licenced driver who
does not fulﬁl one of these criteria was considered to be a professional
driver.
Statistical analysis
Continuous data are expressed as mean with standard deviation (SD)
or median and ﬁrst and third quartile when appropriate; dichotomous
data are presented as numbers and percentages. Cumulative inci-
dences for ﬁrst and second appropriate shock were determined by
the Kaplan–Meier method to take different follow-up times per
patient into account. Cumulative incidences were determined for
several periods of time after implantation and presented with a 95%
conﬁdence interval (CI) as the estimate +1.96 times the standard
error.
Standard errors were derived from the binomial distribution, and
the CI constructed with the normal approximation. The RH formula
was used to calculate the yearly RH to other road users posed by
an ICD-treated driver. With this formula, various outcomes were cal-
culated on the basis of distinct ICD indication (i.e. primary and second-
ary prevention), type of driver (i.e. private and professional driver), and
type of vehicle driven (i.e. heavy truck and passenger-carrying vehicle
or a private automobile). All statistical analyses were performed with
the SPSS software (version 18.0, SPSS Inc., Chicago, IL, USA).
Results
Patients
Since 1996, data of 2786 consecutive patients receiving an ICD for
primary (n ¼ 1718, 62%) or secondary (n ¼ 1068, 38%) preven-
tion were prospectively collected. One hundred and ninety-eight
of these patients [n ¼ 126 (64%) primary prevention; n ¼ 72
(36%) secondary prevention] received an ICD for diagnosed
congenital heart disease or monogenetic heart disease. A total of
196 (7.0%) patients were lost to follow-up; however, they are
included in the analysis as far as data were acquired. Median
follow-up time was 996 days (inter-quartile range, 428–1833
days). The majority of patients [79% men, mean age 61 years
(SD 13 years)] had ischaemic heart disease. Baseline patient
characteristics are summarized in Table 1.
Device therapy in primary prevention
patients
In the group of primary prevention patients, median follow-up was
784 days (inter-quartile range, 363–1495 days). During this
follow-up, a total of 190 (10%) patients received an appropriate
shock. Median time to ﬁrst appropriate shock was 417 days (inter-
quartile range, 134–960 days). From those 190 patients who
received a ﬁrst appropriate shock, 65 patients (34%) received a
second appropriate shock. Median time between ﬁrst
and second appropriate shock was 66 days (inter-quartile range,
29–379 days). Cumulative incidences for ﬁrst and second appro-
priate shock are displayed in Figure 1.
................................................................................
................................................................................
................................................................................
Table 1 Baseline patient characteristics
Total
(n 5 2786)
Primary
prevention
(n 5 1718)
Secondary
prevention
(n 5 1068)
Clinical characteristics
Age (years) 61+13 62+13 61+14
Male (%) 2192 (79) 1336 (78) 856 (80)
Left ventricular
ejection fraction
(%)
33+15 31+14 39+16
QRS, mean (SD),
ms
125+34 129+35 119+32
Renal clearance,
mean (SD),
mL/min
81+37 81+36 82+39
Ischaemic heart
disease (%)
1800 (65) 1077 (63) 723 (68)
History of atrial
ﬁbrillation/ﬂutter
(%)
683 (25) 447 (26) 236 (22)
Medication
ACE-inhibitors/AT
II antagonist (%)
2107 (76) 1407 (82) 700 (66)
Aspirin (%) 1107 (40) 649 (38) 458 (43)
Beta-blocker (%) 1513 (54) 1074 (63) 439 (41)
Diuretics (%) 1738 (62) 1221 (71) 517 (48)
Statins (%) 1610 (58) 1075 (63) 535 (50)
Anti-arrhythmic medication
a
Amiodarone (%) 497 (18) 221 (13) 276 (26)
Sotalol (%) 386 (14) 184 (11) 202 (19)
ACE, angiotensin-converting enzyme; AT, angiotensin; SD, standard deviation.
aPatients could be taking .1 anti-arrhythmic drug.
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median time of 320 days (inter-quartile range, 124–711days).
From the 175 patients with a ﬁrst inappropriate shock, 47
patients (27%) received a second inappropriate shock. Median
time between ﬁrst and second inappropriate shock was 224 days
(inter-quartile range, 77–580 days). Cumulative incidences for
ﬁrst and second inappropriate shock are displayed in Figure 2.
Device therapy in secondary prevention
patients
In the group of secondary prevention patients, median follow-up
time was 1442 days (inter-quartile range, 618–2469 days).
During this follow-up, a total of 342 (32%) patients received an
appropriate shock. Median time to ﬁrst appropriate shock was
509 days (inter-quartile range, 141–1137 days). From those 342
patients with a ﬁrst appropriate shock, 166 (49%) patients received
a second appropriate shock. Median time between the ﬁrst and
second appropriate shock was 400 days (inter-quartile range,
107–1072 days). Cumulative incidences for ﬁrst and second
appropriate shock are displayed in Figure 1.
Inappropriate shocks occurred in 177 (17%) patients with a
median time of 639 days (inter-quartile range, 190–1676 days).
From the 177 patients with a ﬁrst inappropriate shock, 60 patients
(34%) received a second inappropriate shock. Median time
between ﬁrst and second inappropriate shock was 243 (inter-
quartile range, 47–435 days). Cumulative incidences for ﬁrst and
second inappropriate shock are displayed in Figure 2.
Risk assessment in primary prevention
implantable cardioverter deﬁbrillator
patients
In the RH formula (RH ¼ TD × V ×Ac × SCI), the annual RH per
speciﬁc time point is calculated with the pre-speciﬁed variables
TD, V, and Ac and with the SCI. Sudden cardiac incapacitation
equals the cumulative incidence of ICD shocks multiplied by the
proportion of patients experiencing syncope (31%). For instance,
for primary prevention ICD patients, the cumulative incidence
for an appropriate shock at 1 month following implantation is
0.9%. Since the formula uses yearly incidences, the monthly
Figure 1 Kaplan–Meier curve for ﬁrst and second appropriate shock in primary (A) and secondary (B) prevention implantable cardioverter
deﬁbrillator patients. Only patients who received a ﬁrst appropriate shock were included in the analysis for the second appropriate shock.
The time to the occurrence of a second appropriate shock was counted (in days) from the ﬁrst appropriate shock.
Figure 2 Kaplan–Meier curve for ﬁrst and second inappropriate shock in primary (A) and secondary (B) prevention implantable cardioverter
deﬁbrillator patients. Only patients who received a ﬁrst inappropriate shock were included in the analysis for the second inappropriate shock.
The time to the occurrence of a second inappropriate shock was counted (in days) from the ﬁrst inappropriate shock.
Driving restrictions after ICD implantation 2681incidence is converted to a yearly incidence of 10.8% (0.9% × 12)
and hereafter multiplied by the proportion of patients experiencing
syncope or near syncope during an ICD (i.e. 31%) shock. There-
fore, SCI in this example equals 0.03 (0.009 × 12 × 0.31). Accord-
ingly, the RH to other road users per 100 000 ICD patients for
primary prevention ICD patients with private driving habits 1
month after implantation is calculated as follows: 0.04 × 0.28 ×
0.02 × 0.009 × 12 × 0.31 ¼ 0.75. After 1 year, the cumulative
incidence for appropriate shocks in these patients is 6.0% following
implantation. Consequently, the RH to other road users for these
patients declines to 0.43 (RH ¼ 0.04 × 0.28 × 0.02 × 0.062 ×
0.31) per 100 000 ICD patients per year (Figures 1 and 3). Directly
after implantation, the RH to other road users in primary and sec-
ondary prevention ICD patients with private driving habits remains
below the acceptable cut-off value of 5 per 100 000 ICD patients.
Also, after experiencing a ﬁrst inappropriate shock, the RH to
other road users remains below the accepted cut-off value
(Figure 4).
Following an appropriate shock, the annual RH declines from 8.0
(RH ¼ 0.04 × 0.28 × 0.02 × 0.096 × 12 × 0.31) after 1 month to
Figure 3 The annual risk of harm to other road users (y-axis) in primary (A) and secondary (B) prevention implantable cardioverter deﬁ-
brillator patients based on the cumulative incidence of appropriate shocks is illustrated. Risk of harm (solid lines) is calculated in the
months (x-axis) following implantation or appropriate shock. The horizontal dotted line represents the cut-off value for the accepted level
of risk of harm (5 per 100 000). Blue and red dotted lines represent the range of the risk of harm, based on the conﬁdence interval of the
cumulative incidence for appropriate shocks. In primary prevention implantable cardioverter deﬁbrillator patients (A), driving is acceptable
directly following implantation (blue line) and should be restricted for 4 months following appropriate shock (red line). In secondary prevention
implantable cardioverter deﬁbrillator patients (B), driving is acceptable directly following implantation (blue line) and should be restricted for
2 months following appropriate shock (red line).
Figure 4 The annual risk of harm to other road users (y-axis) in primary (A) and secondary (B) prevention implantable cardioverter deﬁ-
brillator patients based on the cumulative incidence of inappropriate shocks is illustrated. Risk of harm (solid lines) is calculated in the
months (x-axis) following implantation or inappropriate shock. The horizontal dotted line represents the cut-off value for the accepted
level of risk of harm (5 per 100 000). Blue and red dotted lines represent the range of the risk of harm, based on the conﬁdence interval
of the cumulative incidence for inappropriate shocks. In primary prevention implantable cardioverter deﬁbrillator patients (A), driving is accep-
table directly following implantation (blue line) as well as directly following inappropriate shock (red line). Similar results were found in
secondary prevention implantable cardioverter deﬁbrillator patients (B), where driving is again acceptable directly following implantation
(blue line) as well as directly following inappropriate shock (red line).
J. Thijssen et al. 26822.1 (RH ¼ 0.04 × 0.28 × 0.02 × 0.302 × 0.31) per 100 000 ICD
patients after 1 year (Figures 1 and 3). In Figure 3, it is shown
that the RH declines below the accepted cut-off value after 4
months following an appropriate shock in primary prevention
ICD patients with private driving habits. However, following an
inappropriate shock, the RH in these patients is again directly
below the accepted cut-off value (Figure 4).
Due to the heavy type of vehicle driven and the hours spent
driving, the annual RH following both implantation and appropriate
shock was found to be 22.3 times higher in primary prevention
ICD patients with professional driving habits when compared
with private drivers. Consequently, the RH to other road users fol-
lowing implantation or shock remains above the acceptable cut-off
value during the complete follow-up.
Risk assessment in secondary prevention
implantable cardioverter deﬁbrillator
patients
In secondary prevention ICD patients with private driving habits,
the annual RH based on an appropriate shock was found to be
1.8 (RH ¼ 0.04 × 0.28 × 0.02 × 0.022 × 12 × 0.31) per 100 000
ICD patients 1 month following implantation (Figures 1 and 3).
Similar to primary prevention ICD patients with private driving
habits, the RH to other road users of these patients remained
below the cut-off value of 5 per 100 000 ICD patients during
follow-up. Also if the RH to other road users after implantation
was based on the cumulative incidence of inappropriate shocks,
outcomes were directly following implantation below the accepted
cut-off value (Figure 4).
However, after an appropriate shock, the RH to other road
users declined from 6.9 (RH ¼ 0.04 × 0.28 × 0.02 × 0.083 × 12
× 0.31) to 2.2 (RH ¼ 0.04 × 0.28 × 0.02 × 0.315 × 0.31) casual-
ties on an annual basis per 100 000 ICD patients 1 month and
12 months following appropriate shock, respectively. This risk fol-
lowing appropriate shock declined below the accepted cut-off
value after 2 months in the group of secondary prevention ICD
patients with private driving habits (Figures 1 and 3). Following an
inappropriate shock, the RH in these patients is again directly
below the accepted cut-off value (Figure 4).
Professional driving in secondary prevention ICD patients was
above the cut-off value following both implantation and shock
during the complete follow-up.
Discussion
In this evidence-based assessment of driving restrictions using the
RH formula, the ﬁndings can be summarized as follows: (i) follow-
ing device implantation, primary and secondary prevention ICD
patients with private driving habits have an acceptable RH and
therefore can be directly permitted to drive; (ii) after an inap-
propriate shock, the level of risk remains below the accepted
cut-off value and therefore no restrictions should be applied in
all ICD patients with private driving habits; (iii) in the case of an
appropriate shock, primary and secondary prevention ICD patients
with private driving habits should be restricted to drive for 4 and 2
months, respectively; (iv) ICD patients with professional driving
habits do not reach an acceptable level of risk during follow-up
and therefore should be permanently restricted to drive.
Risk of driving in primary prevention
implantable cardioverter deﬁbrillator
patients
With increasing rates of primary prevention ICD implantations
worldwide, clear guidelines regarding driving restrictions are essen-
tial. Although the risk for sudden incapacitation while driving is
considered lower in this group of ICD patients than in secondary
prevention ICD patients, no distinction is made in driving restric-
tions following ICD treatment. These differences in event rates
are based on mortality data, rates of sudden cardiac death, and
rate of ICD discharges reported from primary prevention
trials.
20–27 With the lack of randomized controlled trials concern-
ing ICD patients and the risk of driving, recommendations of the
European Heart Rhythm Association (EHRA) and American
Heart Association (AHA) on driving restrictions in the group of
primary prevention ICD patients are based on the data from
these trials.
1,3
Thecurrentstudyshowsacumulativeincidenceof6.0%appropri-
ateshocksafter1year.Furthermore,ICDdischargeswerehighestin
the ﬁrstperiod followingimplantation and showed a slight declinein
the years thereafter (Figure 1). These data are not comparable with
the MADIT I trial, which described a shock rate of 30.0% on an
annual basis during 2 years follow-up or with the MADIT II trial,
which described a shock rate of 11.7% on an annual basis during 3
years follow-up. However, the appropriateness of the deﬁbrillator
discharges could not be assessed reliably in the MADIT I trial.
26,28
Furthermore, the utilized devices of the MADIT II trial were
unable to deliver ATP therapy, which might explain the shock rate
discrepancy between the MADIT II trial and the current study. In
the SCD-HeFT trial, the annual rate of appropriate ICD discharge
during 5 years of follow-up was 7.5% per year.
20 In the DEFINITE
trial, a shock rate of 7.4% occurred on an annual basis; however,
only 44.9% of discharges were appropriate.
25 Data of the
SCD-HeFT and DEFINITE trials are comparable with the data
from the current study.
In the current analysis, 10% of the primary prevention ICD
patients received an inappropriate shock that is more or less com-
parable with the 11.5% of the MADIT II trial.
29
Currently, the EHRA and AHA recommend primary prevention
ICD patients with private driving habits not to drive for 1 month
and 1 week, respectively. It should be noted that this is not
because of an increased risk of SCI, but to improve recovery
from implantation of the deﬁbrillator.
1–3 The current study
demonstrates that the RH for private drivers remains well below
the acceptable cut-off level after implantation and therefore is in
agreement with these recommendations (Figures 3 and 4). In
addition, for professional drivers, the outcomes of the RH
formula in the current analysis are unfavourable during the entire
period of ICD implantation. As a result, based on the outcomes
of this study, these drivers should be permanently restricted
from driving, which is in line with the current recommendations
of the EHRA and AHA.
1–3
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implantable cardioverter deﬁbrillator
patients
Secondary prevention ICD patients have already experienced a
life-threatening arrhythmia (e.g. VT or VF). The probability that
patients will experience a recurrent arrhythmia is therefore an
important factor determining the RH, both with respect to them-
selves as well as others in car accidents. With regard to inappropri-
ate shocks, only 17% of the secondary prevention ICD patients in
the current analysis received such a shock. This proportion is more
or less comparable with the 15% found in secondary prevention
ICD patients included in the PainFREE Rx II trial.
30 However,
the 5-year cumulative incidence of appropriate shock ranged
between 55 and 70% in various trials, compared with a 36% cumu-
lative incidence of appropriate shock in the current analysis.
19,31–34
This difference is at least, in part, explained by the ATP therapy,
which was less frequently applied in the older secondary preven-
tion studies which could prevent degeneration of VT in VF result-
ing in a lower cumulative incidence of appropriate shock therapy in
the present study. Almost similar to Lubinski et al.,
35 the prob-
ability of arrhythmic episodes resulting in appropriate shocks in
the current analysis was 2.2% in the ﬁrst month, 2.9% in the
second month, and remained below 2% per month in the
months thereafter. However, it was assumed that the risk for
road accidents is just a fraction of the monthly probability of
appropriate shocks, as described previously. Therefore, in patients
with deﬁbrillators implanted for secondary prevention, the risk of
symptoms that may lead to incapacity while driving is low. Conse-
quently in the current analysis, the RH to other road users, based
on both the cumulative incidence of appropriate and inappropriate
shocks, remains below the acceptable risk. Therefore, no driving
restrictions for secondary prevention ICD patients with private
driving habits following implantation should be implemented.
However, this outcome is in contrast with the current recommen-
dations for secondary ICD patients with private driving habits,
where the EHRA and AHA recommend a 3 and 6 months
driving restriction, respectively.
1–3
With respect to professional drivers, outcomes of the RH
formula are unfavourable during the entire period. Therefore,
similar to primary prevention patients, secondary ICD patients
should be restricted from professional driving.
Risk of driving following appropriate
or inappropriate shock
A particularly difﬁcult issue for patients and physicians is the con-
sideration of driving restrictions in an ICD patient who has
received an appropriate ICD shock. Following appropriate ICD
therapy, recommendations of the EHRA and AHA prescribe a 3
and 6-month period of driving restriction in ICD patients, respect-
ively.
1,3,36 When patients experience an appropriate shock for a
spontaneous ventricular arrhythmia during follow-up, the risk of
driving is determined by the probability of a subsequent arrhythmic
event and by the likelihood of symptoms of impaired conscious-
ness. However, symptoms of impaired consciousness during the
ﬁrst appropriate ICD therapy are not unambiguously predictive
for future syncope during subsequent shocks.
31,37 In a study of
125 ICD patients by Freedberg et al.,
19 the median freedom
from ICD therapy for the second shock was only 22 days, with a
1-year cumulative incidence of a second appropriate shock being
79%. These were all secondary prevention ICD patients and the
cumulative incidence for a second appropriate shock shows large
dissimilarity when compared with the 1-year cumulative incidence
of 32% observed in the secondary prevention group in the present
study. However, since these are all older devices without the
option of ATP, shock rates in the study by Freedberg et al.a r e
probably comparable with cumulative incidence of all ICD
therapy in the current analysis.
Finally, substituting these cumulative incidences for appropriate
shock in the RH formula results in a signiﬁcant increase in the
RH to other road users when ICD patients are allowed to drive
in the period following this shock. This RH to others is above
the cut-off value of 5 per 100 000 on an annual basis for a
period of 4 months and 2 months following appropriate shock in
primary and secondary ICD patients, respectively (Figure 3).
These outcomes are more or less in line with the recommen-
dations of the EHRA and AHA.
1–3
Since, to our knowledge, the incidence of syncope following an
inappropriate shock is unknown, calculating the corresponding RH
is problematic. Therefore, it was assumed that the incidence of
syncope or near syncope during an inappropriate shock is equal
to the incidence of syncope or near syncope during an appropriate
shock. Even with this apparent defensive approach in which the
potential RH could be overestimated, the actual RH following an
inappropriate shock remained below the acceptable cut-off value
for both primary and secondary ICD patients. Therefore, in line
with the current recommendations of the EHRA and AHA, no
driving restrictions following an inappropriate shock should be
applied in these patients.
1–3 However, it is needless to say that
all efforts should be made to prevent subsequent inappropriate
shock before those patients should be permitted to drive again.
Private and professional drivers
It is, however, important to recognize the difference between the
Canadian and European classiﬁcation of private and commercial
drivers. In Canada, a private driver is deﬁned as one who drives
,36 000 km per year or spends ,720 h driving per year, drives
a vehicle weighing ,11 000 kg, and does not earn a living by
driving. A commercial driver is deﬁned as any licenced driver
who does not fulﬁl the deﬁnition of a private driver. In Europe,
two groups of drivers are deﬁned: Group 1 comprises drivers of
motor cycles, cars, and other small vehicles with or without a
trailer. Group 2 includes drivers of vehicles over 3.5 metric
tonnes or passenger-carrying vehicles exceeding eight seats
excluding.
3
As the RH estimations are based on the Canadian data, it may be
necessary to re-evaluate the strict European rules. For example, a
private driver with a motor-home exceeding the 3.5 metric tonne
limit automatically is a Group 2 driver and restricted from driving
after ICD implant, which seems to be an unnecessary restriction.
Clinical implications
Recently, EHRA and AHA provided consensus documents on
driving restriction for ICD patients. Since no data from routine
J. Thijssen et al. 2684clinical practice were available at that time, restrictions were based
on data from randomized clinical trials, which to a certain extent—
differ from routine clinical practice. This study is the ﬁrst to
provide accurate data on the incidences of appropriate and inap-
propriate shocks during follow-up in routine clinical practice and
based on this, established driving restrictions. However, it is of
course up to the guideline committees and national regulatory
authorities to determine ﬁnal driving restrictions for ICD patients.
It should be emphasized that for the current study, an acceptable
RH of 5 per 100 000 ICD patients was used based on Canadian
consensus. Increasing or decreasing this cut-off value may hold sig-
niﬁcant consequences for the recommendations. Moreover, in the
current formula, Ac was considered 2% (i.e. 2% of reported inci-
dents of driver sudden death or loss of consciousness has resulted
in injury or death to other road users or bystanders). These data
are derived from the Ontario Road Safety Annual Report, since
exact data usable for the formula are scarce. It should be noted
that differences in these data will exist between different countries
or areas affected by population density, driving habits, and type of
vehicle driven. This could affect the RH to other road users.
However, if available, data from other countries can be
implemented in the formula.
2 Finally, guidelines committees and
national regulatory authorities must taken into account the
serious impact of driving restrictions on patient’s life and the fact
that ICD patients will ignore (too rigorous) driving restric-
tions.
38–40
Limitations
This was a prospective observational study assessing the incidence
of SCI in ICD patients. Since patients received ICDs in a single
center over a long period of time, evolving guidelines could have
created a heterogeneous population. Moreover, median follow-up
time was 2.1 years in primary prevention and 4.0 years in second-
ary prevention ICD patients, which resulted in relatively broad CIs
of the cumulative incidences at long-term follow-up. In addition,
ATP was discarded from the analysis since, according to the litera-
ture, minority of patients receiving ATP experience syncope.
10,11
As a result, the calculated RH to others might be underestimated.
Moreover, ICD programming was not homogeneous since ICD
settings were adapted when clinically indicated. Finally, only the
ﬁrst and second shock (appropriate or inappropriate) of the ICD
patients were taken into account. Although patients sometimes
received more than two shocks, the number of patients receiving
three or more shocks was small and had limited follow-up making
assessment of the SCI unreliable.
Conclusion
The current study provides reports on the cumulative incidences
of SCI in ICD patients following ICD implantation and following
ﬁrst appropriate or inappropriate shock. The RH to others was
assessed using this SCI multiplied by the estimated risk of
syncope, which resulted in speciﬁc outcomes for the RH to
other road users per different scenario (Figure 5). This study may
serve as a basis and founding of driving recommendations that
can be used by national regulatory authorities.
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